Quality and Purity: The Pillars of 3-Pyridylacetic Acid Hydrochloride Supply
In the demanding fields of pharmaceutical manufacturing and fine chemical synthesis, the quality and purity of raw materials are non-negotiable. 3-Pyridylacetic Acid Hydrochloride (CAS: 6419-36-9) is no exception. NINGBO INNO PHARMCHEM CO.,LTD. has established itself as a trusted supplier, prioritizing these attributes to meet the exacting standards required by its clientele.
The compound is consistently supplied with an assay of 99.0% or higher, a testament to stringent quality control measures implemented throughout its production. This high level of purity is crucial for several reasons. In pharmaceutical synthesis, impurities can lead to unwanted side reactions, reduced yield, and the potential for toxic byproducts in the final active pharmaceutical ingredient (API). For 3-Pyridylacetic Acid Hydrochloride, which is a key intermediate in the synthesis of drugs like Risedronate sodium, maintaining high purity is paramount for ensuring the safety and efficacy of the end product.
NINGBO INNO PHARMCHEM CO.,LTD. understands that reliability in supply is as important as product quality. The company ensures that its 3-Pyridylacetic Acid Hydrochloride is packaged appropriately, typically in 25 kg drums, and stored under inert atmosphere at room temperature to maintain its stability and prevent degradation. This careful handling ensures that the product reaches customers in optimal condition, ready for immediate use in their synthesis processes.
The focus on quality and purity not only benefits immediate synthesis applications but also supports the long-term research and development efforts of NINGBO INNO PHARMCHEM CO.,LTD.'s partners. By providing a consistently high-grade intermediate, the company enables more predictable experimental outcomes and facilitates the scale-up of successful synthetic routes. This commitment to excellence positions NINGBO INNO PHARMCHEM CO.,LTD. as a dependable partner in the chemical supply chain, fostering innovation and progress in pharmaceutical and chemical industries.
Perspectives & Insights
Future Origin 2025
“In pharmaceutical synthesis, impurities can lead to unwanted side reactions, reduced yield, and the potential for toxic byproducts in the final active pharmaceutical ingredient (API).”
Core Analyst 01
“For 3-Pyridylacetic Acid Hydrochloride, which is a key intermediate in the synthesis of drugs like Risedronate sodium, maintaining high purity is paramount for ensuring the safety and efficacy of the end product.”
Silicon Seeker One
“The company ensures that its 3-Pyridylacetic Acid Hydrochloride is packaged appropriately, typically in 25 kg drums, and stored under inert atmosphere at room temperature to maintain its stability and prevent degradation.”